Project Grant R01AI181635
Award Date
8/9/24
Completion Date
7/31/29
Dollars Obligated
$416K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $857,215 in funding to Hackensack University Medical Center (HUMC) to conduct research on how the fungal pathogen Candida albicans adapts and causes infections in different parts of the human body. The key objectives are to identify and characterize how the C. albicans GCN5 protein, which regulates gene...
This Project Grant award of $314,000.00 from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research Federal Grant Program (CFDA 93.121), supports research to gain insights into the evolution of fungal infections and antimicrobial resistance in the oral environment over the course of HIV infection. The key products and services to be delivered under this award include: 1) Using direct long-read sequencing to profile the fungal...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is funding research at Prokaryotics Incorporated to develop novel antifungal inhibitors targeting the glycosylphosphatidylinositol (GPI) biosynthesis pathway. The $170,000 award, running from February 1, 2025 to January 31, 2027, supports structural elucidation of the C. albicans GPI ethanolamine phosphate transferase enzyme...
This federal Project Grant award, totaling $494,696.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research at the University of Texas Health Science Center at San Antonio (UTHSCSA) to investigate translational control mechanisms that enable the fungal pathogen Candida albicans to respond to host environmental stresses and transition between yeast and filamentous...
This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop an anti-Candida peptide vaccine to reduce fungal burden and morbidity from life-threatening disseminated candidiasis. The $300,000 award to Pop Biotechnologies Inc., a small disadvantaged business in Buffalo, NY, will support the use of a novel liposome-based vaccine adjuvant platform to advance FBA...
This federal Project Grant award, with a total funding amount of $233,670.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The primary objective of this award is to investigate the genetic mechanisms that govern skin colonization by the emerging fungal pathogen Candida auris, which poses a critical public health concern due to its high mortality rate and ability to spread easily...
This $593,860 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will fund the development of phage-polymer nanoparticle conjugates to treat antibiotic-resistant wound biofilm infections. The key products and services to be delivered under this grant include: Synthesis of novel homo- and block copolymers to be non-covalently conjugated with phages effective against...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $866,825 to Brown University to conduct research on how the fungus Candida albicans colonizes the gastrointestinal tract. The research aims to examine the intrinsic mechanisms that allow C. albicans to thrive in the gut, including the role of the toxin candidalysin in enabling the fungus to compete with the...
This $2,917,725 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop novel antifungal agents for treating coccidioidomycosis, a severe fungal infection caused by Coccidioides spp. The key research objectives are to: 1) perform structure-activity relationship (SAR) studies on a lead antifungal candidate compound to optimize its activity; 2) investigate the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $300,000 to support the discovery and development of new antifungal therapeutics. The goal is to identify inhibitors of the fungal enzyme ceramide synthase 1 (CER1), which is essential for fungal growth across different environmental conditions. By targeting CER1, the project aims to develop a more potent antifungal...